Recent Advances in Cervical Cancer Vaccine Development.
- Author:
Woong Shick AHN
1
Author Information
1. Department of Obstetrics and Gynecology, KangNam St. Mary's Hospital, The Catholic University of Korea. ahnws@catholic.ac.kr
- Publication Type:Review
- Keywords:
Cervical cancer;
Vaccine;
HPV
- MeSH:
Adolescent;
Cell Differentiation;
Humans;
Mass Screening;
Mass Vaccination;
Papillomavirus Infections;
Tumor Escape;
Uterine Cervical Neoplasms*;
Vaccination;
Vaccines
- From:Korean Journal of Obstetrics and Gynecology
2005;48(6):1377-1389
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Human papillomavirus infection is often transient and spontaneously reversible. High-risk human papillomavirus persistence is the major cause of cancerous transformation in several tissues. For prophylactic vaccines there is first clinical evidence of effectivity (ie, 100% protection from HPV infection and dysplasia by virus-like particle (VLP) vaccine-induced neutralizing antibodies). Also, Therapeutic vaccines have entered clinical evaluation. While prophylactic VLP vaccines are immunogenic per se, therapeutic vaccines will need further adjuvants to guide T cell differentiation, expansion, survival, and homing to tumor sites. To enhance clinical outcome of successful T cell induction in patients, the susceptibility of the tumor cells for lysis must be addressed in the future, since tumor immune evasion is a severe problem in cervical cancer. Both preventive and therapeutic human papillomavirus vaccinations will probably change our approach to the screening and therapy of human papillomavirus-related diseases in the next few years. The mass vaccination of adolescent patients should lower the frequency of these very frequently lethal infections.
